Ibid. : Part 2 Clinical Symptoms

Neurofibromatosis: part 2--clinical management.

Part 1 of this guideline addressed the differential diagnosis of the neurofibromatoses (NF): neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2) and schwannomatosis (SCH). NF shares some features such as the genetic origin of the neural tumors and cutaneous manifestations, and affects nearly 80 thousand Brazilians. Increasing scientific knowledge on NF has allowed better clinical man...

Burning mouth symptoms, Part II: A clinical review.

Part I of this series presented a review of the literature on Burning Mouth Symptoms (BMS) focusing on its prevalence, its symptoms, and proposed local etiologic factors associated with the condition. Part II will focus on the possible systemic and psychological etiologic factors in order to provide the dental clinician with a perspective on the alternative factors that may cause BMS.

Parkinson's disease--Part 2: Treatment of motor symptoms.

In the absence of a cure, the primary goals in managing Parkinson's disease (PD) are to preserve functionality and health-related quality of life. Meeting these goals can minimize healthcare-resource utilization and long-term healthcare costs. Although effective treatment of motor symptoms of the disease is a central consideration to facilitate improved outcomes, management of nonmotor symptoms...

Common signs and symptoms and unusual diagnoses: part 2.

CLINICAL REVIEW Melanoma—Part 2: management

Mostmelanomas that aredetectedand treated early are cured. However, advanced disease carries a dismal diagnosis, and timely intervention from members of the multidisciplinary skin cancer team at all stages of the disease is essential to maximise cure rates. The management of patients with incurable disease is highly specialised and requires the input of surgeons, medical and clinical oncologist...